{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T18:35:38Z","timestamp":1710873338292},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,3,7]]},"abstract":"<jats:p>In this Viewpoint, officials from the White House Office of National Drug Control Policy describe 3 actions that health care personnel can take to expand prevention and treatment of substance misuse and overdose.<\/jats:p>","DOI":"10.1001\/jama.2023.1090","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T16:01:11Z","timestamp":1675699271000},"page":"707","source":"Crossref","is-referenced-by-count":1,"title":["A 2023 Agenda for Substance Use Prevention and Treatment in the US"],"prefix":"10.1001","volume":"329","author":[{"given":"Rahul","family":"Gupta","sequence":"first","affiliation":[{"name":"White House Office of National Drug Control Policy, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas F.","family":"Wright","sequence":"additional","affiliation":[{"name":"White House Office of National Drug Control Policy, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Holtgrave","sequence":"additional","affiliation":[{"name":"White House Office of National Drug Control Policy, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"jvp230009r1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/add.v117.5","article-title":"Exponential growth of drug overdose poisoning and opportunities for intervention.","volume":"117","author":"Jalal","year":"2022","journal-title":"Addiction"},{"key":"jvp230009r2","unstructured":"White House. Biden-Harris administration announces first-year drug policy priorities. April 1, 2021. Accessed January 9, 2023. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2021\/04\/01\/biden-harris-administration-announces-first-year-drug-policy-priorities\/"},{"key":"jvp230009r3","unstructured":"White House Office of National Drug Control Policy. National drug control strategy. April 21, 2022. Accessed January 9, 2023. https:\/\/www.whitehouse.gov\/wp-content\/uploads\/2022\/04\/National-Drug-Control-2022Strategy.pdf"},{"key":"jvp230009r4","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. Updated January 11, 2023. Accessed January 13, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"jvp230009r5","unstructured":"White House Office of National Drug Control Policy. Dr Rahul Gupta releases statement on CDC\u2019s new overdose death data. Published January 11, 2023. Accessed January 13, 2023. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/01\/11\/dr-rahul-gupta-releases-statement-on-cdcs-new-overdose-death-data-2\/"},{"key":"jvp230009r6","unstructured":"White House Office of National Drug Control Policy and National Highway Traffic Safety Administration. NEMSIS non-fatal opioid overdose surveillance dashboard: January 16, 2022-January 15, 2023. Updated January 29, 2023. Accessed January 23, 2023. https:\/\/nemsis.org\/opioid-overdose-tracker\/"},{"key":"jvp230009r7","unstructured":"Substance Abuse and Mental Health Services Administration. SAMHSA proposes to update federal rules to expand access to opioid use disorder treatment and help close gap in care. December 13, 2022. Accessed January 9, 2023. https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/20221213\/update-federal-rules-expand-access-opioid-use-disorder-treatment"},{"key":"jvp230009r8","unstructured":"US Food and Drug Administration. FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. November 8, 2022. Accessed January 9, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801405\/jama_gupta_2023_vp_230009_1677717750.10203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T16:05:43Z","timestamp":1678205143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.1090","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}